[{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"M-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"M-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"COVID-19 Nanosized Antibodies","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital Corp"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Society","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Society","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Society"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Innovation"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Alpaca\u2011derived Nanosized Antibody","moa":"IL-17A","graph1":"Dermatology","graph2":"Discovery","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 NanoAb","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NanoAb COVID-19 Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"VHH-Antibody","moa":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ BiondVax Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Scinai Immunotherapeutics \/ BiondVax Pharmaceuticals"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NanoAb-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Scinai Immunotherapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
